Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Bevurogant in Healthy Japanese Males
NCT03793621Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2019
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in psoriasis comparing Bevurogant (BI 730357) with Placebo (2 arms). Primary endpoint: Number of Participants With Drug-related Adverse Events. Started Jan 2019; status: completed.
02
Drugs
bevurogant
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT03793621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03793621.